News

30.07.
2025

The Berlin BioScience Academy (BBA), formerly "Gläsernes Labor Akademie (GLA)" and the Verband Biologie, Biowissenschaften und Biomedizin in Deutschland (VBIO e.V.) are offering the "Biotech & Pharma Business Summer School - from Target to Market" again this year. From 09 - 12 September 2025, the orientation course provides young professionals who are thinking about starting a career in drug development or are already working there with a compact overview of the overall industry process of drug development, including its complex regulatory, legal and organizational requirements.

In biomedical research, the identification of a "target", i.e. a site to bind for an active ingredient against a specific disease, usually marks the starting point for the development of a new drug. However, most development candidates do not make it to market approval. On average, it takes 12 years and costs the manufacturer more than 1 billion euros until a new drug is released for the first patients.

The planning, execution and evaluation of studies in the many stages of preclinical and clinical development in a framework of highest regulatory requirements and global competition require an efficient interaction of international teams and newest technology. The complexity of modern drug development poses challenges and risks, but also offers many career prospects for young scientists from the life sciences.

The aim of the course is to provide a solid understanding of the individual phases of drug development and thus enable the attendees to orient themselves in potential fields of activity in biotechnology and the pharmaceutical industry.

The trainer team of the "Biotech & Pharma Business Summer School" consists of altogether nine experts from the pharmaceutical industry, biotech companies, leading Contract Research Organizations (CROs) and patent attorney offices. They will guide participants through the various phases of drug development, from idea to market maturity, with keynote speeches, workshops. The lecture by Prof. Wolf-Dieter Ludwig, head of the German Medicines Commission with a critical view of the validity of clinical studies in oncology will round off the seminar program.

The course fee per person is 2.035,00 € plus 19% VAT. Participants from academic institutions pay 1,630.00 € plus VAT; 10% discount for members of VBIO and its professional societies.

The Berlin BioScience Academy (BBA) - Practice-oriented and innovative knowledge transfer in the life sciences
The Berlin BioScience Academy (BBA), formerly Gläsernes Labor Akademie (GLA), supports young scientists throughout Germany in their professional orientation and entry into the pharmaceutical and biotechnology industry. It offers technical assistants and laboratory technicians in-service training on current topics in the life sciences.
Our focus is on a close connection between science and business. It enables the conception, certification and implementation of a practice-oriented continuing training program with a top-class team of experts from research institutions and industry. The life science program includes summer schools, laboratory courses, seminars, webinars and congresses. In addition, the BBA regularly invites people to the BerlinBioCube to exchange ideas. The “Talks in the Cube” network biotech companies and research institutions, investors and associations.

For more information, please visit https://www.glaesernes-labor-akademie.de/de/biotech-pharma .

For further questions please contact Dr. Uwe Lohmeier (u.lohmeier@campusberlinbuch.de , Tel: +49 30-9489-2935).